PMID- 25127393
OWN - NLM
STAT- MEDLINE
DCOM- 20150916
LR  - 20221207
IS  - 2044-5385 (Print)
IS  - 2044-5385 (Electronic)
IS  - 2044-5385 (Linking)
VI  - 4
IP  - 8
DP  - 2014 Aug 15
TI  - Clinical features and treatment outcome in newly diagnosed Chinese patients with 
      multiple myeloma: results of a multicenter analysis.
PG  - e239
LID - 10.1038/bcj.2014.55 [doi]
AB  - The aim of this study was to understand the clinical features and treatment 
      outcome of Chinese patients with multiple myeloma (MM). This retrospective study 
      enrolled 940 newly diagnosed inpatients (median age, 59 years; immunoglobulin 
      (Ig)D isotype, 6.5%) with complete follow-up data at three centers. In all, 85.8% 
      of patients were of Durie-Salmon stage III and 48.3% were of International 
      Staging System (ISS) stage III at diagnosis. Also, 9.6% of patients had 
      extramedullary plasmacytoma. Compared with IgG, IgD-type patients were diagnosed 
      at a younger age, and more patients were of ISS stage III, with hypercalcemia, 
      elevated levels of lactate dehydrogenase, hyperuricemia, renal dysfunction and 
      1q21 amplification (P=0.03). The overall survival (OS) benefit was more prominent 
      in IgG than in IgD when patients received bortezomib; however, they showed no 
      significant difference when they received older therapies such as melphalan 
      combined with prednisone or vincristine combined with adriamycin and 
      dexamethasone. Fluorescence in situ hybridization (FISH) results showed that 
      17.6% had 17p13 deletion. Conventional cytogenetics revealed that 13.3% were 
      hypodiploid and those cases had the worst survival, but hyperdiploid cases (9.3%) 
      did not show any survival benefit compared with those with a normal karyotype 
      (77.4%). Median OS and progression-free survival for all patients were 54 and 26 
      months, respectively. Significant factors for survival by multivariate analysis 
      were gender, ISS stage, number of FISH abnormalities and extramedullary disease. 
      MM in mainland China presents with different features, with patients being of 
      younger age and having higher risk and more survival benefit in IgG patients 
      receiving bortezomib.
FAU - Lu, J
AU  - Lu J
AD  - Department of Hematology, People's Hospital, Beijing University, Beijing, China.
FAU - Lu, J
AU  - Lu J
AD  - Department of Hematology, The Myeloma & Lymphoma Center, Changzheng Hospital, The 
      Second Military Medical University, Shanghai, China.
FAU - Chen, W
AU  - Chen W
AD  - Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, 
      Beijing, China.
FAU - Huo, Y
AU  - Huo Y
AD  - Beijing University Clinical Research Institute, Beijing, China.
FAU - Huang, X
AU  - Huang X
AD  - Department of Hematology, People's Hospital, Beijing University, Beijing, China.
FAU - Hou, J
AU  - Hou J
AD  - Department of Hematology, The Myeloma & Lymphoma Center, Changzheng Hospital, The 
      Second Military Medical University, Shanghai, China.
CN  - Chinese Medical Doctor Association Hematology Branch
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20140815
PL  - United States
TA  - Blood Cancer J
JT  - Blood cancer journal
JID - 101568469
SB  - IM
CIN - Acta Haematol. 2016;136(3):140-6. PMID: 27409804
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Asian People
MH  - China
MH  - Chromosome Deletion
MH  - Chromosomes, Human, Pair 17/genetics
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Multiple Myeloma/diagnosis/genetics/metabolism/mortality/pathology
MH  - Neoplasm Staging
MH  - Survival Rate
PMC - PMC4219472
EDAT- 2014/08/16 06:00
MHDA- 2015/09/17 06:00
PMCR- 2014/08/01
CRDT- 2014/08/16 06:00
PHST- 2013/09/29 00:00 [received]
PHST- 2014/06/02 00:00 [revised]
PHST- 2014/07/02 00:00 [accepted]
PHST- 2014/08/16 06:00 [entrez]
PHST- 2014/08/16 06:00 [pubmed]
PHST- 2015/09/17 06:00 [medline]
PHST- 2014/08/01 00:00 [pmc-release]
AID - bcj201455 [pii]
AID - 10.1038/bcj.2014.55 [doi]
PST - epublish
SO  - Blood Cancer J. 2014 Aug 15;4(8):e239. doi: 10.1038/bcj.2014.55.